After weeks of disruption to scientific federal grants, the National Institutes of Health has fallen behind in funding ...

IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...

Q3 2025 Management View CEO Shawn Singh outlined the company’s progress on its lead clinical programs, particularly fasedienol, which is being developed for the acute treatment of social anxiety ...

In December 2024, the Company announced a strategic restructuring of its business operations, including the potential divestiture of its DNA Tagging and Security Products and Services ("DNA Tagging") ...

Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles ...

The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) stock soared over 20% following the announcement that the company will receive a ...

This $15M payment marks the second milestone achieved in the collaboration with Merck. Under the agreement, Neuphoria is eligible to receive up to $450M in additional milestone payments for certain ...

Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, has raised €2.7 million from existing ...

Insilico Medicine ( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced a set of preclinical drug discovery benchmarks from the 22 ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...